Failure to share and make use of existing knowledge, particularly negative research outcomes, has been recognized as one of the key sources of waste and inefficiency in the drug discovery and development process. In the field of antibiotic research, providing a platform where negative outcomes could be shared to prevent the vicious cycle of duplicating costly studies that produce the same negative results would greatly de-risk and accelerate the development of new antibiotics. Providing a legally supported framework that recognizes negative outcomes as intellectual contributions, which can subsequently be translated into a revenue-sharing model, may lead to more openness and value creation in support of a sustainable and responsible transformation of research into socially and economically beneficial innovations.

未能分享和利用现有知识，尤其是负面研究成果，已被认为是药物发现和开发过程中浪费和效率低下的主要来源之一。在抗生素研究领域，提供一个可以共享负面结果的平台，以防止重复产生相同负面结果的昂贵研究的恶性循环，这将大大降低风险并加速新抗生素的开发。提供一个法律支持的框架，将负面结果视为智力贡献，随后可以转化为收入分享模式，可能会带来更多的开放和价值创造，以支持可持续和负责任的研究向社会和经济有益的创新转变。